Therapeutic effect of early intensive antihypertensive treatment on rebleeding and perihematomal edema in acute intracerebral hemorrhage

J Clin Hypertens (Greenwich). 2019 Sep;21(9):1325-1331. doi: 10.1111/jch.13629. Epub 2019 Jul 26.

Abstract

To observe the effect of early intensive blood pressure (BP)-lowering treatment on rebleeding and perihematomal edema (PE) in patients with acute intracerebral hemorrhage (ICH). A total of 121 patients with ICH were randomly assigned to an early intensive antihypertensive treatment group (IG) (n = 62) or control group (CG) (n = 59). For both groups, 25 mg of urapidil injection was slowly administered intravenously in 6 hours of the onset. For the IG, 100 mg of urapidil and 30 mL of 0.9% sodium chloride were then slowly administered. Repeat computed tomography imaging was performed at 24 hours, 72 hours, day 7, and day 14 to detect any rebleeding via changes in hematoma volume and the changes in PE. Finally, NIHSS scores and Barthel Index (BI) were calculated at 24 hours, 72 hours, day 7, day 14, day 30, and day 90. The average hematoma volume in IG patients was significantly smaller than that of CG patients after 24 hours (P < .05). The volume of PE in the CG increased more than in the IG within 24 hours of onset, but was not statistically significant (P > .05); however, this trend was statistically significant after 72 hours (P < .05). On day 30 and day 90, the average NIHSS score of IG patients was lower than that of CG patients, and the BI was higher (P < .05) than that of CG patients. There was no significant difference in mortality between the two groups. Early intensive antihypertensive treatment in ICH patients reduces rebleeding and PE, improving short-term quality of life.

Keywords: acute intracerebral hemorrhage; early intensive antihypertensive treatment; perihematomal edema; rebleeding.

MeSH terms

  • Acute Disease
  • Administration, Intravenous
  • Adrenergic alpha-1 Receptor Antagonists / administration & dosage
  • Adrenergic alpha-1 Receptor Antagonists / therapeutic use
  • Aged
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use*
  • Brain Edema / diagnostic imaging
  • Brain Edema / drug therapy*
  • Brain Edema / prevention & control
  • Case-Control Studies
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / mortality
  • Cerebral Hemorrhage / pathology
  • Comorbidity
  • Early Medical Intervention / statistics & numerical data
  • Female
  • Hematoma / diagnostic imaging
  • Hematoma / drug therapy*
  • Hematoma / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use
  • Quality of Life
  • Time Factors
  • Tomography, X-Ray Computed / methods

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • Antihypertensive Agents
  • Piperazines
  • urapidil